Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
May 31, 2026
,
Atkins, M. et al.
ASCO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Fc-Enhanced Anti-CTLA-4 Antibody, Botensilimab, Enhances the Efficacy of Multiple Therapeutic Modalities in Immunotherapy-Refractory Tumor Models
SITC
Society for Immunotherapy of Cancer (SITC)
November 7, 2024
,
Levey, et al.
No items found.
AGEN1721
AGEN1721, a First-in-Class FC-Enhanced Bifunctional Antibody Targeting FAP and TGFB, Remodels the Tumor Microenvironment to Overcome Cancer-Associated Fibroblast-Mediated Immune Suppression
SITC
Society for Immunotherapy of Cancer (SITC)
November 7, 2024
,
Iyer et al.
No items found.